Icatibant Teva

Icatibant Acetate, the active ingredient in Icatibant Teva, is a bradykinin B2 receptor antagonist presented as a subcutaneous injection for subcutaneous use. It is indicated for the treatment of acute attacks of hereditary angioedema in patients with C1‑inhibitor deficiency.

GNH USA supplies Icatibant Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing and regulatory support for this specialty therapeutic. The company adheres to stringent quality standards and offers cold‑chain logistics where required.

Icatibant Teva acts on the bradykinin‑mediated pathway that underlies hereditary angioedema. It is used for the following recognized indications: - Hereditary angioedema (C1‑inhibitor deficiency): reduces swelling and pain during acute attacks. - Hereditary angioedema type I: provides rapid symptom relief when attacks occur. - Hereditary angioedema type II: blocks bradykinin‑driven vascular leakage to control episode severity.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or erythema: localized skin reddening. - Swelling at injection site: transient edema. - Nausea: occasional gastrointestinal upset. - Headache: mild to moderate intensity. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Severe hypotension: sudden drop in blood pressure. - Angioedema of the face or airway: potentially life‑threatening swelling. - Urticaria: widespread hives. - Thrombocytopenia: low platelet count. - Severe injection‑site necrosis: rare tissue damage.

Before using Icatibant Teva, consider the following precautions: - Pregnancy: safety not established; use only if potential benefit justifies the risk. - Breastfeeding: caution advised; limited data on excretion in milk. - Renal impairment: monitor renal function and adjust therapy as needed. - Concomitant ACE inhibitors: may increase risk of bradykinin‑related angioedema. - Hypersensitivity: avoid in patients with known allergy to icatibant or excipients. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant Teva may interact with other medicines. Review the following categories: Major Interactions (Avoid): - ACE inhibitors: combined use can heighten the risk of angioedema. - DPP‑4 inhibitors: potential additive effect on bradykinin pathways. Moderate Interactions (Monitor Closely): - Estrogen‑containing therapies: may influence bradykinin metabolism. - NSAIDs: could increase local injection‑site reactions. - Other B2 receptor antagonists: additive pharmacologic activity may require dose adjustment.